TheStreet downgraded shares of Kalvista Pharmaceuticals (NASDAQ:KALV) from a c- rating to a d+ rating in a report published on Thursday, TheStreetRatingsTable reports.
KALV has been the subject of a number of other research reports. Needham & Company LLC upped their target price on Zuora from $27.00 to $30.00 and gave the stock a strong-buy rating in a report on Wednesday, March 20th. ValuEngine cut Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. Roth Capital reaffirmed a buy rating on shares of Kalvista Pharmaceuticals in a report on Tuesday, May 28th. BidaskClub cut Vertex Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 9th. Finally, Zacks Investment Research cut ExlService from a hold rating to a sell rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. Kalvista Pharmaceuticals presently has a consensus rating of Buy and an average target price of $29.40.
Kalvista Pharmaceuticals stock opened at $17.31 on Thursday. Kalvista Pharmaceuticals has a 52 week low of $7.95 and a 52 week high of $34.92. The stock’s fifty day simple moving average is $20.59. The firm has a market cap of $298.60 million, a PE ratio of -11.31 and a beta of 2.12.
In other news, CFO Benjamin L. Palleiko sold 3,073 shares of the stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $25.70, for a total value of $78,976.10. Following the completion of the sale, the chief financial officer now owns 33,573 shares of the company’s stock, valued at $862,826.10. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Benjamin L. Palleiko sold 1,073 shares of the stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $25.51, for a total value of $27,372.23. Following the completion of the sale, the chief financial officer now directly owns 33,573 shares of the company’s stock, valued at approximately $856,447.23. The disclosure for this sale can be found here. In the last three months, insiders sold 25,501 shares of company stock valued at $645,553. Insiders own 38.40% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Flinton Capital Management LLC acquired a new stake in shares of Kalvista Pharmaceuticals in the fourth quarter valued at about $26,000. Bank of Montreal Can boosted its position in shares of Kalvista Pharmaceuticals by 28.5% during the 1st quarter. Bank of Montreal Can now owns 5,824 shares of the specialty pharmaceutical company’s stock valued at $166,000 after purchasing an additional 1,292 shares in the last quarter. Marshall Wace North America L.P. bought a new stake in shares of Kalvista Pharmaceuticals during the 1st quarter valued at about $175,000. Tibra Equities Europe Ltd bought a new stake in shares of Kalvista Pharmaceuticals during the 1st quarter valued at about $727,000. Finally, Marshall Wace LLP bought a new stake in shares of Kalvista Pharmaceuticals during the 1st quarter valued at about $843,000. 80.64% of the stock is owned by institutional investors.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Featured Article: Oversold
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.